Evidence map›Paper›PMID 16235096›Full record

ArticleHuman genetics2005

Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR.

Cynthia Helms, Nancy L Saccone, Li Cao, Jil A Wright Daw, Kai Cao, Tony M Hsu, Patricia Taillon-Miller, Shenghui Duan, Derek Gordon, Brandon Pierce and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Human genetics, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Psoriasis: An Immunogenetic Perspective.Global medical genetics · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Inhibitory KIR3DL1 alleles are associated with psoriasis.The British journal of dermatology · 2016
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Skin barrier disruption: a requirement for allergen sensitization?The Journal of investigative dermatology · 2012
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Cynthia HelmsDepartment of Genetics, Washington University School of Medicine, Box 8232, 4566 Scott Avenue, St. Louis, Missouri, 63110, USA.
Nancy L Saccone
Li Cao
Jil A Wright Daw
Kai Cao
Tony M Hsu
Patricia Taillon-Miller
Shenghui Duan
Derek Gordon
Brandon Pierce
Jurg Ott
John Rice
Marcelo A Fernandez-Vina
Pui-Yan Kwok
Alan Menter
Anne M Bowcock
Washington University in St. Louis · USBaylor University Medical Center · USGeorgetown University · USThe University of Texas MD Anderson Cancer Center · US

Funding

TECHNOLOGIES FOR DIALLELIC MARKER DISCOVERY AND TESTINGR01HG001720 · NHGRI · WASHINGTON UNIVERSITY · PI KWOK, PUI-YAN · 1997 to 2007
$9.6M
GENETIC ANALYSIS OF PSORIASISR01AR044577 · NIAMS · WASHINGTON UNIVERSITY · PI BOWCOCK, ANNE MARY · 1998 to 2001
$729k
NHGRI NIH HHS HG01720NIAMS NIH HHS AR04904901NIAMS NIH HHS AR44577
6 · The paper itself

Abstract

Psoriasis is a complex inflammatory disease of the skin affecting 1-2% of the Caucasian population. Associations with alleles from the HLA class I region (now known as PSORS1), particularly HLA-Cw*0602, were described over 20 years ago. However, extensive linkage disequilibrium (LD) within this region has made it difficult to identify the true susceptibility allele from this region. A variety of genes and regions from a 238-kb interval extending from HLA-B to corneodesmosin (CDSN) have been proposed to harbor PSORS1. In order to identify the minimum block of LD in the MHC class I region associated with psoriasis we performed a comprehensive case/control and family-based association study on 242 Northern European psoriasis families and two separate European control populations. High resolution HLA typing of HLA-A, -B and -C alleles was performed, in addition to the genotyping of 18 polymorphic microsatellites and 36 SNPs from a 772-kb segment of the HLA class I region harboring the previously described interval. This corresponded on average to one SNP every 7 kb in the candidate 238 kb region. With all tests, the association was the strongest with single markers and haplotypes from a block of LD harboring HLA-C and SNP n.9. Logistic regression analyses indicated that association seen with candidate genes from the interval such as CDSN and HCR was entirely dependent on association with HLA-Cw*0602 and SNP n.9-G alleles. The previously reported association with CDSN and HCR was observed to be due to the existence of the associated alleles lying on the most commonly over-transmitted haplotype. Rare over-transmitted haplotypes also harbored HLA-Cw*12 alleles. HLA-Cw*12 family members are closely related to HLA Cw*0602, sharing identical sequences in their alpha-2 domains, peptide-binding pockets A, D and E and all 3' introns. The introduction of a potential binding site for the RUNX/AML family of transcription factors in intron 7, is also specific to these HLA-C alleles. These variants need to be investigated further for their role as PSORS1.

Indexed as

Case-Control StudiesChromosome MappingGenetic Predisposition to DiseaseGlycoproteinsHaplotypesHLA-C AntigensHumansIntercellular Signaling Peptides and ProteinsIntracellular Signaling Peptides and ProteinsPedigreePolymorphism, Single NucleotideProteinsPsoriasisRegression AnalysisCCHCR1 protein, humanCDSN protein, humanGlycoproteinsHLA-C AntigensIntercellular Signaling Peptides and ProteinsIntracellular Signaling Peptides and ProteinsProteinsPSORS1C1 protein, human

Identifiers

PMID16235096
OpenAlexW2019630743

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.